Open access peer-reviewed chapter

Epigenetic: New Insight in Gestational Diabetes Mellitus

Written By

Maria Grazia Dalfrà, Silvia Burlina and Annunziara Lapolla

Submitted: September 14th, 2021Reviewed: September 29th, 2021Published: December 8th, 2021

DOI: 10.5772/intechopen.100854

Chapter metrics overview

86 Chapter Downloads

View Full Metrics

Abstract

Gestational diabetes mellitus (GDM) is the more frequent metabolic complication of pregnancy with a prevalence that is significantly increased in the last decade accounting for 12–18% of all pregnancies. Recent evidences strongly suggests that epigenetic profile changes could be involved in the onset of GDM and its related maternal and fetal complications. In particular, the unfavorable intrauterine environment related to hyperglycemia, a feature of GDM, has been evidenced to exert a negative impact on the establishment of the epigenome of the offspring. Furthermore the adverse in utero environment could be one of the mechanisms engaged in the development of adult chronic diseases. The purpose of this article is to review a number of published studies to fill the gap in our understanding of how maternal lifestyle and intrauterine environment influence molecular modifications in the offspring, with an emphasis on epigenetic alterations.

Keywords

  • gestational diabetes
  • epigenetic
  • maternal complications
  • fetal complications

1. Introduction

Gestational diabetes mellitus (GDM), defined as a glucose intolerance developing or first recognized during pregnancy that is not clearly overt diabetes [1], is increasingly worldwide due mainly to a rising rates of obesity [2, 3, 4, 5, 6, 7].

GDM, if not properly diagnosed and/or treated can lead to adverse outcomes for the mother and the child both during and after pregnancy [8, 9, 10]. Of note women experiencing GDM and their children are at high risk to develop cardiometabolic diseases (type 2 diabetes, obesity, hyperlipemia, metabolic syndrome, hypertension, cardiovascular disease) later in life [8, 9, 10].

Insulin resistance and beta-cell disfunction are the main physiopathological mechanisms involved in GDM development [4, 5, 6, 7]. However all the actors involved are not completely understood as an intricate network of metabolic pathways work in pregnancy complicated by GDM, that includes an abnormal expression of proteins involved in glucose and lipid metabolism, inflammation, oxidative stress, immune response, organ development, and cell death regulation. In this context recent studies have suggested that genetic, epigenetic and environmental factors contributes in GDM development [11, 12, 13, 14], (Figure 1). In addition, the adverse intrauterine environment in patients with GDM could also have a negative impact on the establishment of the epigenomes of the offspring [15, 16].

Figure 1.

Factors contributing to GDM development.

The purpose of this article is to review a number of published studies to fill the gap in our understanding how the intrauterine environment can determine molecular modifications in the offspring, with an emphasis on epigenetic alterations.

Advertisement

2. Epigenetic: the meaning

Epigenetic is the study of changes in gene expression caused by mechanisms not involving variations in DNA sequences but determining changes as DNA methylation, histone modifications, and messenger RNA (mRNA) binding by microRNAs (miRNAs).

The study of epigenetic modifications can therefore be useful in deepening and clarifying the pathogenesis of GDM as well as in the use of markers for diagnosis, risk prediction and follow up of different types of pathologies as GDM.

Methylation of cytosine on CpG in the DNA so determining the formation of methylcytosine (5-mc) is the first studied DNA modification. Methylation can determine an increased gene expression by silencing some repressor elements, but, in some regions of DNA as the promoter ones, it can reduce gene expression by inhibiting the activity of enhancer elements [17].

Histone modification can influence the gene expression by modifying the chromatin packing [18].

Micro RNAas are small non-coding single stranded RNAs of about 22 nucleotides that are involved in post-trancriptional regulation of gene expression. It has been evidenced that miRNAs can affect the stability and translation of RNA [19]. Interestingly, some recently-identified miRNAs have been associated with insulin secretion, insulin resistance, and inflammation in patients affected by type 2 diabetes [14].

Advertisement

3. Epigenetic and GDM

It has been demonstrated that even slight increases in glycemia can be associated with epigenetic adaptations via the so-called “metabolic memory”, and in this context few studies have examined the association between methylation and GDM development. Of note Whu and coworkers firstly identified two differently methylated genes in plasma, umbilical cord and placenta samples of pregnant women that develop GDM, the Hook Microtubule Tethering Protein 2 (HOOK2), and Retinol Dehydrogenase 12 (RDH12). HOOK2 is a protein that mediates binding to organelles, and is involved in cilia morphogenesis and endocytosis. RDH12 encodes a retinal reductase involved in short-chain aldehyde metabolism [20] (Tables 1 and 2).

GeneAuthors
MothersHOOK2WHU, 2016
RDH12Whu,2016
H3K27Michialczy 2016
H3K4Michialczy 2016
PlacentaADIPOQBouchard 2010
TNFRSF1BCardenas 2018
LDLRCardenas2018
BLMCardenas 2018
PDE4BCardenas 2018
ABCA1Houde 2013
MESTHajj 2018
NR3C1Hajj 2018
OffspringNR3C1Hajj 2018
PYGO1Allard 2015
CLN8Allard 2015
PRDM16Côté 2016
BMP7Côté 2016
PPARGC1aCôté 2016
MESTHajj 2018
ATPSA1Haerle 2017
NFAP4Haerle 2017
PRKCHHaerle 2017
SLC17AHaerle 2017

Table 1.

Gene methylation in gestational diabetes mellitus.

miRNAmiRNA impairedAuthor
MothersmiR-132Reduced expressionZhou et al. 2019
Zhao et al. 2011
miR29aReduced expressionZhao et al. 2011
miR222Reduced expressionZhao et al. 2011
miR16-5pUp-regulationCao et al. 2017
miR17–5pUp-regulationCao et al. 2017
miR20a-5pUp-regulationCao et al. 2017
miR 155-5pOverexpressionWander et al. 2017
miR 21–3pOverexpressionWander et al. 2017
miR210-3pOverexpressiionWander et al. 2017
PlacentamiR98Up-regulationCao et al. 2016

Table 2.

Studies assessing the role of mRNAs in gestational diabetes.

In this frame more studies have been performed evaluating microRNA: Zhao and coworkers [21], evidenced that the expression of miR222, miR-132 and miR-29a was significantly lower in women who were diagnosed as affected by GDM at 24–28 WG with respect to non GDM control pregnant women. MiR-29 has a role in glucose homeostasis, in particular when overexpressed reduce the insulin-stimulated glucose uptake and the gluconeogenesis [22]. MiR-132 is involved in the regulation of cytochrome P450,mediated by insulin, furthermore when its expression is reduced impairs the correct development of trophoblast, [14, 22].

Successively, as omental adipose tissue is known to play a role in insulin resistance in GDM, the differential expression patterns of miRNAs in omental adipose tissues from GDM patients and pregnant women with normal glucose tolerance was studied [23]. MiR-222 was found to be significantly up-regulated in GDM by quantitative real-time PCR and its expression was related with serum estradiol levels, whereas the expressions of estrogen receptor (ER)-α protein and insulin-sensitive membrane transporter glucose transporter 4 (GLUT4) protein were markedly reduced. Then in order to silence miR-222 in 3 T3-L1 adipocytes the antisense transfection oligonucleotides of miR-222 was applied. An important increase of the expressions of ERα and GLUT4, the insulin-stimulated translocation of GLUT4 from the cytoplasm to the cell membrane and of the uptake of glucose was evidenced in mature adipocites. On the basis of their results the authors conclude that: “miR-222 is a potential regulator of ERα expression in estrogen-induced insulin resistance in GDM and could be a candidate biomarker and therapeutic target for GDM”.

Cao and coworkers [24], in 85 pregnant women with GDM found that the relative and absolute expression of plasma microRNA-16-5p, −17-5p, −20a-5p were significantly upregulated, with respect to 72 pregnant women without GDM. During pregnancy, the expression of those microRNAs from GDM women were also positively correlated with insulin resistance. Furthermore, significative differences were found in GDM women with respect to normal pregnant ones in the plasma levels of microRNA-16-5p, −17-5p, −20a-5p and in the areas under the curve (0.92, 0.88, and 0.74, respectively). The authors conclude that plasma microRNA-16-5p, −17-5p and -20a-5p are potential diagnostic biomarkers in GDM. MiR16.5 is implicated in the insulin sensitivity regulation and it is upregulated in type 2 diabetes. MiR17–5 has a role is the proliferation of smooth muscle cell. MiR20a-5p is upregulated in preeclampsia, a well known complication of diabetic pregnancy.

Wander and coworkers [25] analyzed the role of miRNA in women affected by GDM and different body mass index. MiR155-5p, and 21–3p were found positively associated with GDM. The miR-21-3p and miR-210-3p were positively associate only in GDM overweight/obese women. MiR-155 and MiR21–3 have a role in pathways that regulate cell survival, and inflammation. MiR210-3p is associated with angiogenesis [14].

As for histone modification, Michalczyk and coworkers [26], analyzed several epigenetic markers during and after pregnancy in a small, multiethnic population. The evaluation of the proportion of total H3 histone methylated GDM women who developed type 2 diabetes after pregnancy showed a significantly lower H3K27 (50%)with respect to non-diabetic women; furthermore type2 diabetic women with previous GDM had also significantly lower H3K4 (75%) with respect to GDM with normal glucose tolerance after pregnancy. A study evaluating a large sample size for a longer post partum follow up is however necessary to confirm that histone methylation could be a useful predictor of type 2 diabetes in women with GDM.

Advertisement

4. Epigenetic and placenta

The placenta undergoes a number of structural and functional changes in pregnant women affected by diabetes due to the increased production of inflammatory cytokines determined by the high levels of maternal glucose [27]. In this frame, utilizing different mass spectrometry approaches - such as MALDI-MS and LC-MSE – in the evaluation of placental samples from women with and without GDM, it has been showed that if well controlled, GDM induces only minor changes in the placental proteome [28]. So it is of interest to verify if epigenetic modifications can however occur at the placental level even with relatively low maternal glucose levels and if the extent of these modifications is in some way related to glycemic levels (Tables 1 and 2).

Lesseur and coworkers investigate the relations between prepregnancy obesity and GDM and placental leptin DNA methylation on 535 mother-neonate enrolled in the Rhode Island Child health Study. The results of the study showed that neonates of mothers affected by GDM had higher placenta leptin methylation levels similar to those of the mothers with prepregnancy obesity. So maternal metabolic milieu before and during pregnancy can determine impairment of placenta methylation so contributing to the metabolic fetal programming of obesity [29]. These data well fit with those reported by Bouchard et al. [30]. In a subsequent paper Bouchard et al. [31], evaluated the possible association between the methylation of adiponectin gene (ADIPOQ) in plasma cord blood and placenta tissue and plasma glucose levels of pregnant women. They found low DNA methylation levels in the ADIPOQ promoter on the fetal side of the placenta that were positively related with high maternal glucose levels in the second trimester of pregnancy. Furthermore, the low DNA methylation levels on the maternal side of the placenta were also positively related to insulin resistance, assessed with the homeostasis model assessment method (HOMA), and to high circulating adiponectin levels during pregnancy.

Furthermore, a negative correlation between DNA methylation of the ATP-binding cassette transporter A1 (ABCA1) gene on the placenta maternal site and HDL and 2 hour OGTT plasma glucose was found in 26 GDM women. When looking at the placenta fetal site, DNA methylation of ABCA1 was negatively associated with cord blood tryglicerides [32].

In a well conducted study, Cao et al. aim to verify the role of miRNA-98 in placental tissues from GDM patients, considering that MiRNA-98 is implicated in the correct embryo implantation [33]. They showed that, in the placentas of GDM patients miR-98 is upregulated and total DNA methylation levels are reduced with respect to normal pregnant women. These results,considering that MiRNA-98 regulates the Mecp2 target gene a key protein for embrio development, coud have important consequences for fetal growth.

More recently Cardenas and coworkers [34] conducted an elegant epigenome-wide association study (involving 850,000 CpG sites) on samples of placenta and plasma glucose, and related them to 2 h post-OGTT plasma glucose levels in 448 mother-and-infant pairs at 24–30 weeks of gestation. They found a lower DNA methylation of 4 CpG sites within the phosphodiesterase 4b gene that are positively correlated with plasma glucose at 2 h OGTT. Furthermore, a differentially methylation behavior in relation with maternal glucose was found for 3 CpG sites in the TNFRSF1B, LDLR and BLM.

DNA methylation correlated with expression of its respective genes in placental tissue at three out of four independent identified loci:PDE4B, TNFRSF1B, and LDLR. TNFRSF1B is involved in apoptosis, LDLR encodes a lipoprotein receptor that mediates LDL endocytosis in the cells, and is also expressed in the placenta. BLM is associated with genome stability and maintenance. So maternal glycemic levels during pregnancy were associated with placental DNA methylation of inflammatory genes, the expression of which depends on epigenetic changes.

Advertisement

5. Epigenetic and offspring

The Developmental Origins of Health and Disease, largely derived from the Barker hypothesis [16], strongly suggests that not only undernutrition but also overnutrition, maternal obesity and diabetes can determine chronic diseases in the offspring through an early exposure to a suboptimal fetal environment; in this context epigenetic modifications have been showed to contribute mainly to this (Table 1).

Hajj et al. [35], have evaluated the effect of GDM on the epigenome of the offspring. To reach this aim they analyzed cord blood and placental tissue from the newborn of GDM patients 88 of them treated with diet and 98 with insulin. The results of the study show meaningful lower methylation levels in GDM compared with pregnant women without GDM in the levels of the maternal imprinting MEST gene and the non-imprinting glucocorticoid receptor NR3C1 gene. It is to notice that these genes are associated with placental and fetal growth. Low levels of MEST methylation have also been found in plasma of adults with obesity with respect to normal-weight controls. So the intrauterine exposure to GDM has effects on the epigenome of the offspring, and epigenetic malprogramming of MEST can contribute to predisposing individuals to obesity later in life.

The effect of the exposure to maternal diabetes in utero has been investigated by a genome-wide methylation analysis on peripheral mononuclear cell’s DNA in 21 healthy children of GDM mothers, by utilizing a mediation analysis [36]. A series of genes have been identified to be associated with cardiometabolic risk among that the ubiquitin proteasome system (UPS) was the most important. An increased methylation of PYGO1 and CLN 8 showed the most important mediation effect on VCAM-1 levels of the children. TheVCAM-1 protein mediates the adhesion of lymphocytes, monocytes, eosinophils, and basophils to vascular endothelium. It also functions in leukocyte-endothelial cell signal transduction, and it may play a role in the development of atherosclerosis.

A 2 step epigenetic Mendelian randomization approach was used by Allard et al. on data of 485 mothers and their children [37]. To take into consideration maternal glycemia, a genetic risk score, based on 10 known genetic variant related to glycemia, was firstly developed (GRs 10). The results of the study showed that an high GRs 10 was associated with a lower methylation of cg 12083122 that is located near the leptin gene. The low methylation levels at cg12083122 was associated with high cord leptin levels, so evidencing that maternal glycemia can influence offspring leptin epigenetic modulation. In this frame, to evaluate the possible relation of maternal hyperglycemia and DNA methylation of genes involved in brown adipose tissue activation, the DNA methylation levels were measured in placenta samples from normal and GDM women and compared to results of maternal plasma glucose levels. The values of maternal plasma glucose, at the second and third trimester of pregnancy, resulted correlated with the methylation levels of PRDM16, BMP 7 and PPARGC1a and with cord blood leptin levels. These results suggest that maternal glycemia can determine modification in genes related to obesity development in the offsring [38]. More recently, an Illumina 450 K methylation arrays was utilized to analyze genome-wide methylation patterns in fetal cord blood of pregnant women with and without GDM. Significant differences in methylation were found between the GDM patients and the normal pregnant women; furthermore, these differences were more significant in GDM women treated with insulin. A series of genes were found modified by methylation and in particular: ATPSA1, which encodes a subunit of mitochondrial ATP synthetase that acts also reducing mitochondrial oxidation; MFAP4, which is engaged in the process of cell adhesion and intercellular interaction; PRKCH, a component of the protein C family engaged in numerous signaling pathways; and SLC17A, or sodium/phosphate cotransporter involved in hypoxia events. It is to emphasize that these methylation modifications even if had a small effect size, affects many genes/loci [39]. Furthermore, methylation that affects a series of genes that can impair insulin secretion and increase the risk of diabetes and obesity has been reported in offspring of mother affected by type 2 diabetes a condition that shares the same physiopathological mechanisms of GDM [40].

Advertisement

6. Conclusions

The studies taken into consideration made a significant contribution to the knowledge of the physiopathological basis of GDM and of its complications, however methodological problems, small sample size, different GDM diagnostic criteria, make difficult to have final conclusion.

Further researches with high study power need to be undertaken in order to be more confident on the role of epigenetic in GDM disease, bearing also in mind that epigenetic expression in pregnancy varies with weeks of gestation, sex of the fetus, ethnicity, type of sample considered. These studies must be able to determine new road for intervention so to reduce in GDM patients and their children the development of the chronic metabolic diseases [41, 42].

Advertisement

Abbreviations

GDMGestational diabetes mellitus
miRNAsmicroRNAs
CpGC-phosphate-G sites
5-mcmethylcytosine
HOOK2Hook Microtubule Tethering Protein 2
RDH12Retinol Dehydrogenase 12
ERestrogen receptor (ER)-α protein
GLUT4sodium glucose transporter 4
H3K27
H3K4H3K4 histone
MALDI-MSMatrix-Assisted Laser Desorption/Ionization Mass Spectrometry
LC-MSELiquid Chromatography / Mass Spectrometry
ADIPOQHuman Adiponectin, C1Q and Collagen Domain
HOMAHomeostasis Model Assessment Method
ABCA1ATP-Binding Cassette Transporter A1
Mecp2
TNFRSF1BTNF Receptor Superfamily Member 1B
LDLR
BLMBLM RecQ Like Helicase
MEST
NR3C1Nuclear Receptor Subfamily 3 Group C Member 1
UPSUbiquitin Proteasome System
PYGO1Pygopus Family PHD Finger 1
CLN 8
VCAMHuman Vascular Cell Adhesion Molecule 1
GRs 10Genetic Risk Score
PRDM16PR Domain Containing 16
BMP 7
PPARGC1aPeroxisome Proliferator Activated Receptor Gamma
ATPSA1Subunit of Mitocondrial ATP Synthetase
MFAP4Microfibril Associated Protein 4
PRKCHProtein Kinase C family
CTBP2C-Terminal Binding Protein 2

References

  1. 1.International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International Association of Diabetes and Pregnancy Study Groups: Recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010; 33: 676-668
  2. 2.Koning SH, Hoogenberg K, Lutgers HL, Van den Berg PP, Wolffenbuttel BHR. Gestational diabetes mellitus: current knowledge and unmet needs. J Diabetes. 2016; 8(6): 770-781
  3. 3.Lapolla A, Metzger BE. The post-HAPO situation with gestational diabetes: the bright and dark sides. Acta Diabetol. 2018; 55(9):885-892
  4. 4.Ryan EA, Enns L. Role of gestational hormones in the induction of insulin resistance. J Clin Endocrinol Metab. 1988; 67:341-347
  5. 5.Kampmann U, Knorr S, Fuglsang J, Ovesen P. Determinants of Maternal Insulin Resistance during Pregnancy: An Updated Overview. J Diabetes Res. 2019 Nov 19;2019:5320156. doi: 10.1155/2019/5320156. PMID: 31828161; PMCID: PMC6885766
  6. 6.Lain K, Catalano PM. Metabolic changes in pregnancy. Clin Obstet Gynaecol.2007; 50:938- 948
  7. 7.Lapolla A, Dalfrà MG, Mello G, Parretti E, Cioni R, Marzari C et al. Early detection of insulin sensitivity and beta-cell function with simple tests indicates future derangements in late pregnancy. J Clin Endocrinol Metab. 2008; 93:876-880
  8. 8.Burlina S, Dalfrà MG, Lapolla A. Short- and long-term consequences for offspring exposed to maternal diabetes: a review. J Matern Fetal Neonatal Med. 2019; 32(4):687-694
  9. 9.Lowe WL, Scholtens DM, Lowe LP, Kuang A, Nodzenky M, Talbot O et al. Association of gestational diabetes with maternal disorders of glucose metabolism and childhood adiposity. JAMA. 2018;11;320(10):1005-1016
  10. 10.Burlina S, Dalfrà MG, Lapolla A.Clinical and biochemical approach to predicting post-pregnancy metabolic decompensation. Diabetes Res Clin Pract. 2018;145:178-183
  11. 11.Whu L, Cui L, Tam WH, Ma RC, Wang CC. Genetic variants associated with gestational diabetes mellitus: a meta-analysis and subgroup analysis. Scientific Reports. 2016; 6: 30539
  12. 12.Pantham P, Aye IL, Powell T. Inflammation in maternal obesity and gestational diabetes mellitus. Placenta. 2015; 36:709-715
  13. 13.Lapolla A, Dalfrà MG, Sanzari M, Fedele D, Betterle C, Masin M et al. Lymphocyte subsets and cytokines in women with gestational diabetes mellitus and their newborn. Cytochine. 2005; 31:280-287
  14. 14.Zhu H, Leung SW. Identification of microRNA biomarkers in type 2 diabetes: a meta-analysis of controlled profiling studies. Diabetologia. 2015; 58: 900-911
  15. 15.Agarwal P, Morriseau TS, Kereliuk SM, Doucette CA, Wicklow BA, Dolinsky VW. Maternal obesity, diabetes during pregnancy and epigenetic mechanisms that influence the developmental origins of cardiometabolic disease in the offspring. Crit Rev Clin Lab Sci. 2018; Mar;55(2):71-101. doi: 10.1080/10408363.2017.1422109. Epub 2018 Jan 8. PMID:29308692
  16. 16.Barker DJ. The fetal and infant origins of adult disease. BMJ. 1990; 301:1111-1122
  17. 17.Hernando-Herraez I, Garcia-Perez R, Sharp AJ, Marques-Bonet T. DNA Methylation: Insights into Human Evolution. PLoS Genet. 2015; Dec 10;11(12):e1005661. doi: 10.1371/journal.pgen.1005661. PMID: 26658498; PMCID: PMC4684328
  18. 18.Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol. 2005 Nov;6(11):838-849. doi: 10.1038/nrm1761. PMID:16261189
  19. 19.Zhao S, Liu MF. Mechanisms of microRNA-mediated gene regulation. Sci China C Life Sci. 2009 Dec;52(12):1111-1116. doi: 10.1007/s11427-009-0152-y. Epub 2009 Dec 17. PMID:20016967
  20. 20.Whu P, Farrel W E, Haworth K E, Emes RD, Kitchen MO, Glossop JR, Fryer AA. Maternal genome-wide DNA methylation profile in gestational diabetes shows distinctive disease-associated changes relative to matched healthy pregnancies. Epigenetics.2016; 13: 122-128
  21. 21.Zhao C, Dong J, Jiang T, Shi Z, Yu B, Zhu Y et al. Early second trimester serum miRNA profiling predicts gestational diabetes mellitus. PLoS ONE. 2011: 6:23925-23923
  22. 22.Zhou X, Xiang C, Zheng X. MiR-132 serves as a diagnostic biomarker in gestational diabetes mellitus and its regulatory effect on trophoblast cell viability. Diagnostic Pathology. 2019; 14:119-128
  23. 23.Shi Z, Zhao C, Guo X, Ding H, Cui Y, Shen R, Liu J. Differential expression of microRNAs in omental adipose tissue from gestational diabetes mellitus subjects reveals miR-222 as a regulator of ERα expression in estrogen-induced insulin resistance. Endocrinology. 2014; May;155(5):1982-90. doi: 10.1210/en.2013-2046. Epub 2014 Mar 6. PMID:24601884
  24. 24.Cao YL, Jia YJ, Xing BH, Shi DD, Dong XJ. Plasma microRNA-16-5p, 17-5p and 20a-5p: novel diagnostic biomarkers for gestational diabetes mellitus. Obstet Gynecol Res 2017; 43:974-981
  25. 25.Wander PL, Boyko EJ, Hevner K, Parikin VJ, Tadesse MG, Sorensen TK et al. Circulating early- and mid-pregnancy microRNAs and risk of gestational diabetes. Diab Res Clin Pract. 2017; 132:1-9
  26. 26.Michalczyk AA, Dunbar JA, Janus ED, Best JD, Ebeling PR, Ackland MJ et al. Epigenetic markers to predict conversion from gestational diabetes to type 2 diabetes. J Clin Endocrinol Metab. 2016; 101: 2396-2404
  27. 27.Hauguel-de Mouzon S, Desoye G The placenta in diabetic pregnancy: new methodological approaches. In Gestational Diabetes: a decade after the HAPO study. Lapolla A, Metzger BE eds, Frontier in Diabetes Karger 2020; pp 145-154
  28. 28.Burlina S, Banfi C, Brioschi M, Visentin S, Dalfrà MG, Traldi P, Lapolla A. Is the placenta proteome impaired in well-controlled gestational diabetes? J Mass Spectrom. 2019; 54:359-365
  29. 29.Lesseur C, Armstrong DA, Paquette AG, Li Z, Padbury JF, Marsit CJ. Maternal obesity and gestational diabetes are associated with placental leptin DNA methylation. Am J Obstet Gynecol. 2014; Dec;211(6):654.e1-9. doi: 10.1016/j.ajog.2014.06.037. Epub 2014 Jun 19. PMID: 24954653; PMCID: PMC4254188
  30. 30.Bouchard L, Thibault S, Guay SP, Santure M, Monpetit A, St-Pierre J et al. Leptin gene epigenetic adaptation to impaired glucose metabolism during pregnancy. Diabetes Care. 2010; Nov;33(11):2436-41. doi: 10.2337/dc10-1024. Epub 2010 Aug 19. PMID: 20724651; PMCID: PMC2963508
  31. 31.Bouchard L, Hivert M, Guay SP, StPierre J, Perron P, Brisson D. Placental adiponectin gene DNA methylation levels are associated with mother’s blood glucose concentration. Diabetes. 2012; 61:1272-1280
  32. 32.Houde AA, Guay SP, Desgagné V, Hivert MF, Baillargeon JP, St-Pierre J et al. Adaptations of placental and cord blood ABCA1 DNA methylation profile to maternal metabolic status. Epigenetics. 2013; Dec;8(12):1289-302. doi: 10.4161/epi.26554. Epub 2013 Oct 10. PMID: 24113149; PMCID: PMC3933490
  33. 33.Cao JL, Zhang L, Lin J, Tian S, Lv XD, Wang XQ et al. Up-regulation of miR-98 and unravelling regulatory mechanisms in gestational diabetes mellitus. Sci Rep.2016; 6:32268-32274
  34. 34.Cardenas A, Gagnè-Quellet V, Allard C, Brisson D, Perron P, Bouchard L et al. Placental DNA methylation adaptation to maternal glycemic response in pregnancy. Diabetes. 2018; 67: 1673-1683
  35. 35.Hajj NE, Pliushch G, Schneider E, Dittrich M, Muller T, Korenov M et al. Metabolic programming of MEST DNA methylation by intrauterine exposure to gestational diabetes mellitus. Diabetes. 2018; 62: 1320-1328
  36. 36.West NA, Kechris K, Dabelea D. Exposure to Maternal Diabetes in Utero and DNA Methylation Patterns in the Offspring. Immunometabolism. 2013; Mar;1:1-9. doi: 10.2478/immun-2013-0001. PMID: 23741625; PMCID: PMC3670583
  37. 37.Allard C, Desgagné V, Patenaude J, Lacroix M, Guillemette L, Battista MC, et al. Mendelian randomization supports causality between maternal hyperglycemia and epigenetic regulation of leptin gene in newborns. Epigenetics. 2015;10(4):342-51. doi: 10.1080/15592294.2015.1029700. PMID: 25800063; PMCID: PMC4622547
  38. 38.Côté S, Gagné-Ouellet V, Guay SP, Allard C, Houde AA, Perron P et al. PPARGC1α gene DNA methylation variations in human placenta mediate the link between maternal hyperglycemia and leptin levels in newborns. Clin Epigenetics. 2016; Jun 22;8:72. doi: 10.1186/s13148-016-0239-9. PMID: 27340502; PMCID: PMC4918074
  39. 39.Haerle L, Haj N, Dittrich M, Muller T, Nanda I, Lehnen H. Epigenetic signatures of gestational diabetes mellitus on cord blood methylation. Clinical Epigenetics.2017; 9:28-38
  40. 40.Chen P, Piaggi P, Traurig M, Bogardus C, Knowler WC, Baier LJ, Hanson RL. Differential methylation of genes in individuals exposed to maternal diabetes in utero. Diabetologia. 2017;Apr;60(4):645-655. doi: 10.1007/s00125-016-4203-1. Epub 2017 Jan 26. PMID: 28127622; PMCID: PMC7194355
  41. 41.Michels K. Epigenetics epidemiology. 2012. Dondrecht New York Springer Verlag
  42. 42.Ibarra A, Vega-Guedes B, Brito-Casillas Y, Wagner A Diabetes in pregnancy and microRNAs :promises and limitations in their clinical applications. Non-coding RNA; 2018; 4:1-250

Written By

Maria Grazia Dalfrà, Silvia Burlina and Annunziara Lapolla

Submitted: September 14th, 2021Reviewed: September 29th, 2021Published: December 8th, 2021